Athersys (ATHX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Athersys Reports Second Quarter 2016 Results
August 9, 2016 4:03 PM EDTCLEVELAND, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) today announced its financial results for the three months ended June 30, 2016.
Highlights of the second quarter of 2016 include:
Successful discussions with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on ischemic stroke study design and requirements, led by HEALIOS K.K. (Healios) with Athersys support, laying the groundwork for study initiation later this year;Productive discussions with U.S. Food and Drug Administration (FDA) about the design of our planned international Phase 3 study of MultiStem® treatment for... More